Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the first dual PPAR alpha/delta agonist for rare cholestatic liver disease primary biliary cholangitis (PBC).

GSK has reported promising results with a drug to treat the severe itching that plagues patients with rare cholestatic liver disease primary biliary cholangitis (PBC). Interim results from the ...

New treatment options include: extension of the length of proton pump inhibitor-based triple therapies, sequential therapy, quadruple therapy, levofloxacin-based triple or quadruple therapy.

Fluoroquinolones are a class of antibiotics approved to treat or prevent certain types of bacterial infections. They were discovered in the 1960s, and doctors began to prescribe them in the ...

Objective: To assess the efficacy, safety and tolerability of moxifloxacin, an 8-methoxy fluoroquinolone, in patients with respiratory tract infections (RTIs) treated in general practice in ...

A boxed warning is the sternest warning issued by the U.S. Food and Drug Administration (FDA) that a medication can carry and still remain on the market in the United States. A boxed warning appears ...

Treating a urinary tract infection (UTI) aims to relieve symptoms, destroy the infection, and prevent it from recurring. Antibiotics can often provide instant UTI relief and are considered first-line ...